onecle - legal research

Court Opinions

US Supreme Court
US Tax Court
Board of Patent Appeals

State Laws

Alabama
Arizona
California
Florida
Georgia
Illinois
Indiana
Massachusetts
Michigan
Nevada
New Jersey
New York
North Carolina
Oregon
Pennsylvania
Texas
Virginia
Washington

US Code

1 USC - General Provisions
2 USC - The Congress
3 USC - The President
4 USC - Flag and Seal
5 USC - Gov't Organization
6 USC - Domestic Security
7 USC - Agriculture
8 USC - Aliens and Nationality
9 USC - Arbitration
10 USC - Armed Forces
11 USC - Bankruptcy
12 USC - Banks and Banking
13 USC - Census
14 USC - Coast Guard
15 USC - Commerce and Trade
16 USC - Conservation
17 USC - Copyrights
18 USC - Crimes
19 USC - Customs Duties
20 USC - Education
21 USC - Food and Drugs
22 USC - Foreign Relations
23 USC - Highways
24 USC - Hospitals
25 USC - Indians
26 USC - Internal Revenue Code
27 USC - Intoxicating Liquors
28 USC - Judiciary
29 USC - Labor
30 USC - Mineral Lands
31 USC - Money and Finance
32 USC - National Guard
33 USC - Navigation
34 USC - Navy (repealed)
35 USC - Patents
36 USC - Patriotic Societies
37 USC - Uniformed Services
38 USC - Veterans' Benefits
39 USC - Postal Service
40 USC - Public Property
41 USC - Public Contracts
42 USC - Public Health
43 USC - Public Lands
44 USC - Public Printing
45 USC - Railroads
46 USC - Shipping
47 USC - Telecom
48 USC - Territories
49 USC - Transportation
50 USC - War

US Constitution

Preamble
Art. I - Legislative
Art. II - Executive
Art. III - Judicial
Art. IV - States' Relations
Art. V - Mode of Amendment
Art. VI - Prior Debts
Art VII - Ratification

21 USC 356c - Discontinuance of life saving product

Legal Research Home > US Code > Food and Drugs > 21 USC 356c - Discontinuance of life saving product

Sec. 356c. Discontinuance of life saving product

(a)
In general
A manufacturer that is the sole manufacturer of a drug—
(1) that is—
(A) life-supporting;
(B) life-sustaining; or
(C) intended for use in the prevention of a debilitating disease or condition;
(2) for which an application has been approved under section 355 (b) or 355 (j) of this title; and
(3) that is not a product that was originally derived from human tissue and was replaced by a recombinant product,
shall notify the Secretary of a discontinuance of the manufacture of the drug at least 6 months prior to the date of the discontinuance.
(b)
Reduction in notification period
The notification period required under subsection (a) of this section for a manufacturer may be reduced if the manufacturer certifies to the Secretary that good cause exists for the reduction, such as a situation in which—
(1) a public health problem may result from continuation of the manufacturing for the 6-month period;
(2) a biomaterials shortage prevents the continuation of the manufacturing for the 6-month period;
(3) a liability problem may exist for the manufacturer if the manufacturing is continued for the 6-month period;
(4) continuation of the manufacturing for the 6-month period may cause substantial economic hardship for the manufacturer;
(5) the manufacturer has filed for bankruptcy under chapter 7 or 11 of title 11; or
(6) the manufacturer can continue the distribution of the drug involved for 6 months.
(c)
Distribution
To the maximum extent practicable, the Secretary shall distribute information on the discontinuation of the drugs described in subsection (a) of this section to appropriate physician and patient organizations.

Sections:  Previous  355c  355d  355e  356  356-1  356a  356b  356c  357  358  359  360  360a  360b  360c  Next

Last modified: July 21, 2011


Business Contracts